Author

E. J. Shpall

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:cancer & tumor microenvironment· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:mouse· 2

Frequent Co-Authors

J. Wang· 3 shared D. Mak· 2 shared D. Marin· 2 shared E. Ensley· 2 shared E. Gokdemir· 2 shared F. Meng· 2 shared H. Shaim· 2 shared I. M. MERAZ· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Wang

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model

I. M. MERAZ, M. Majidi, R. Song, F. Meng, L. Gao, Q. Wang, J. Wang, E. J. Shpall, J. A. Roth

This study shows NPRL2 gene therapy reduces lung metastases in KRAS/STK11 mutant NSCLC in humanized mice by enhancing immune cell infiltration and reducing T cell inhibitory signals.

bioRxiv · Mar 26, 2024Cancer Biology

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib

I. M. Meraz, M. Majidi, B. Fang, F. Meng, L. Gao, R. Shao, R. Song, F. Li, M. J. Ha, Q. Wang, J. Wang, E. J. Shpall, S. Y. Jung, F. Haderk, P. Gui, , J. A. Roth

This study identifies PDK1 as a driver of osimertinib resistance in NSCLC, showing its inhibition sensitizes resistant cells and correlates with disease progression.

bioRxiv · Dec 10, 2021Cancer Biology

Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment

Z. Schwabkey, D. Wiesnoski, C.-C. Chang, W.-B. Tsai, D. Pham, S. S. Ahmed, T. Hayase, M. R. Ortega Turrubiates, R. K. El-Himri, C. A. Sanchez, E. Hayase, A. C. Frenk Oquendo, T. Miyama, T. M. Halsey, B. E. Heckel, , E. J. Shpall

The paper links diet-derived metabolites and mucus to fever after cytotoxic cancer treatment by showing how Akkermansia muciniphila affects colonic mucus and inflammation.

bioRxiv · Sep 18, 2021Microbiology

Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy

R. Basar, N. Uprety, E. Ensley, M. Daher, K. Klein, F. Martinez, F. Aung, M. Shanley, B. Hu, E. Gokdemir, M. Mendt, F. Reyes Silva, S. Acharya, T. Laskowski, L. Muniz-Feliciano, , K. Rezvani

The paper expands SARS-CoV-2 T-cells from COVID-19 donors using IL-2/4/7 cytokines, achieving >1000-fold expansion with preserved function, and inactivates the glucocorticoid receptor to create glucocorticoid-resistant T-cells for adoptive therapy.

bioRxiv · Sep 15, 2020Immunology

CIS checkpoint deletion enhances the fitness of cord blood derived natural killer cells transduced with a chimeric antigen receptor

K. Rezvani, M. Daher, R. Basar, E. Gokdemir, N. Baran, N. Uprety, M. Mendt, L. Kerbauy, M. Hernandez Sanabria, N. Imahashi, A. Nunez, L. Li, M. Fathi, A. Rezvan, V. Mohanty, , Wei Inn

This paper combines CIS checkpoint deletion with CAR engineering in NK cells to enhance their metabolic fitness and anti-tumor activity in a lymphoma model.

bioRxiv · Mar 29, 2020 · PreprintImmunology